


ReCLAIM-2

Dry Age-Related Macular Degeneration



A phase 2, randomized, double-masked, placebo-controlled clinical study to evaluate the safety, efficacy and pharmacokinetics of subcutaneous injections of elamipretide in subjects with dry age-related macular degeneration (AMD) with geographic atrophy (GA).



Over
10M
Americans
are impacted
by AMD

PARTICIPANTS

The trial will assess approximately 180 patients who have at least 1 eye with dry AMD with GA.

TRIAL SITES



40 sites in the
United States

TRIAL BEGAN



Q1 2019

ENDPOINTS

PRIMARY

- Safety and tolerability
- Low-luminance best-corrected visual acuity

SECONDARY

- Low-luminance reading acuity
- Best-corrected visual acuity
- GA area as measured by fundus autofluorescence
- GA area as measured by optical coherence tomography